Overview

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

Status:
Withdrawn
Trial end date:
2017-08-04
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation, phase I study of the combination of MLN9708 plus Nelfinavir.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Treatments:
Glycine
Ixazomib
Nelfinavir
Proteasome Inhibitors